Funded Startups in Seattle
Across these 50 Seattle-area rounds (most recent Nov 24, 2025; oldest Apr 15, 2025), the largest disclosed amount is Avalara’s $500M on 2025-11-13, which d…
Across these 50 Seattle-area rounds (most recent Nov 24, 2025; oldest Apr 15, 2025), the largest disclosed amount is Avalara’s $500M on 2025-11-13, which dwarfs every other disclosed round in the table. By comparison, the next-largest disclosed amounts cluster far below it: Sana Biotechnology’s $86M (2025-08-06), Omnidian’s $87M (2025-04-21), Avalyn Pharma’s $100M (2025-07-22), and Phaidra’s $50M (2025-10-04). Disclosures also show two notable “unknown” patterns: 3 rounds are marked undisclosed (Cosmos Innovation 2025-11-24; Ocean 2025-08-26; Flyhomes 2025-07-01) and 14 rounds use “Venture - Series Unknown/Series Unknown” (e.g., Cosmos Innovation, Prelude 2025-09-26, Arzeda 2025-09-09). Sector-wise, healthcare/biotech is repeatedly represented (e.g., Lumen Bioscience $30M on 2025-10-07; Sana Biotechnology $86M on 2025-08-06; Omeros $22M on 2025-07-24; Brook Health $28M on 2025-10-19), while AI shows up across multiple stages (Seed through Series B), from BluePill ($6M, 2025-11-21) to Phaidra ($50M, 2025-10-04).
Most recent rounds
50 shownRelated listings
Frequently asked
How does the largest disclosed Seattle-area round compare to the rest of the disclosed amounts in this list?
Avalara’s $500M (2025-11-13) is the only disclosed round above $100M, and it is far above the next tier that includes Avalyn Pharma’s $100M (2025-07-22) and then Sana Biotechnology’s $86M (2025-08-06) and Omnidian’s $87M (2025-04-21).
Are there temporal clusters where many rounds land close together?
Yes. A dense run appears in late October to mid-November 2025, including InsForge ($2M, 2025-11-22), Aeone ($4M, 2025-11-21), BluePill ($6M, 2025-11-21), Avalara ($500M, 2025-11-13), and Cosmos Innovation (undisclosed on 2025-11-24).
What’s the “unknown disclosure” pattern, and which named deals carry it?
Three deals are explicitly undisclosed: Cosmos Innovation (undisclosed, 2025-11-24), Ocean (undisclosed, 2025-08-26), and Flyhomes (undisclosed, 2025-07-01). Separately, 14 rounds are labeled “Series Unknown” or “Venture - Series Unknown,” such as Prelude ($16M, 2025-09-26) and Arzeda ($5M, 2025-09-09).
Does the funding profile skew toward a particular stage, or is it spread widely across stages?
It’s spread but not uniform: multiple Seed rounds are visible (e.g., BluePill $6M on 2025-11-21; TestSprite $7M on 2025-10-30; Row Zero $10M on 2025-05-06), while large later-stage rounds cluster in biotech/healthcare (Lumen Bioscience Series C $30M on 2025-10-07; Brook Health Series B $28M on 2025-10-19; Omnidian Series C $87M on 2025-04-21).
Are there outliers besides the $500M round that stand out for size or context?
Yes. On the low end, Akin shows a $0K disclosed amount on 2025-04-21, which sits at the floor of disclosed values. On the high end (but still far below Avalara), biotech/healthcare rounds like Avalyn Pharma $100M (2025-07-22) and Sana Biotechnology $86M (2025-08-06) form a second concentration above the $20M–$50M band (e.g., Membrion $20M on 2025-10-06; Phaidra $50M on 2025-10-04).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.